Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera

Journal of Immunological Methods

Volumn 337, Issue 1, 2008, Pages 16-23

  Sogo, Takahiro ^a   Kawahara, Masahiro ^a   Tsumoto, Kouhei ^a   Kumagai, Izumi ^b   Ueda, Hiroshi ^a   Nagamune, Teruyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Antibody variable region; Chimeric receptor; Growth control; Interleukin 2 receptor; T cell

Indexed keywords

ENZYME ANTIBODY; ERYTHROPOIETIN RECEPTOR; HYHEL 10 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DNA MODIFICATION; HEN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; INTERLEUKIN-3; LYMPHOCYTE ACTIVATION; MICE; MURAMIDASE; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TIME FACTORS; TRANSFECTION;

EID: 48949115595     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.05.003     Document Type: Article

References (29)

1. + T cells of human IL-2 receptor beta-chain transgenic mice. J. Immunol. 153 (1994) 5373
2. - tumor cells. Blood 92 (1998) 4248
3. Brielmeier M., Bechet J., Falk M.H., Pawlita M., Polack A., and Bornkamm G.W. Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection. Nucleic Acids Res. 26 (1998) 2082
4. Cheever M.A., and Chen W. Therapy with cultured T cells: principles revisited. Immunol. Rev. 157 (1997) 177
5. Cooper L.J.N., Ausubel L., Gutierrez M., Stephan S., Shakeley R., Olivares S., Serrano L.M., Burton L., Jensen M.C.V., Forman S.J., and DiGiusto D.L. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8 (2006) 105
6. Ellery J.M., and Nicholls P.J. Alternate signaling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev. 13 (2002) 27
7. high but not other T cells. J. Immunol. 164 (2000) 5659
8. Gillis S., and Smith K.A. Long term culture of tumour-specific cytotoxic T cells. Nature 268 (1977) 154
9. Greiser J.S., Stross C., Heinrich P.C., Behrmann I., and Hermanns H.M. Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. J. Biol. Chem. 277 (2002) 26959
10. Jiang N., He T.C., Miyajima A., and Wojchowski D.M. The box1 domain of the erythropoietin receptor specifies janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera. J. Biol. Chem. 271 (1996) 16472
11. Kawahara M., Kimura H., Ueda H., and Nagamune T. Selection of genetically modified cell population using hapten-specific antibody/receptor chimera. Biochem. Biophys. Res. Commun. 315 (2004) 132
12. Kawahara M., Ogo Y., Tsumoto K., Kumagai I., Ueda H., and Nagamune T. Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimer. Cytotechnology 52 (2006) 171
13. Kawahara M., Ueda H., Morita S., Tsumoto K., Kumagai I., and Nagamune T. Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch. Nucleic Acids Res. 31 (2003) e32
14. Knutson K.L., Almand B., Mankoff D.A., Schiffman K., and Disis M.L. Adoptive T-cell therapy for the treatment of solid tumours. Exp. Opin. Biol. Ther. 2 (2002) 1
15. Kragel A.H., Travis W.D., Feinberg L., Pittaluga S., Striker L.M., Roberts W.C., Lotze M.T., Yang J.J., and Rosenberg S.A. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum. Pathol. 21 (1990) 493
16. Leen A.M., Rooney C.M., and Foster A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25 (2007) 243
17. Lord J.D., McIntosh B.C., Greenberg P.D., and Nelson B.H. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164 (2000) 2533
18. Morita S., Kojima T., and Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7 (2000) 1063
19. Mule J.J., Shu S., Schwarz S.L., and Rosenberg S.A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225 (1984) 1487
20. Nakamura Y., Russell S.M., Mess S.A., Friedmann M., Erdos M., Francois C., Jacques Y., Adelstein S., and Leonard W.J. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 369 (1994) 330
21. Nelson B.H., Lord J.D., and Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 369 (1994) 333
22. Nishi M., Ishida Y., and Honjo T. Expression of functional interleukin-2 receptors in human light chain/Tac ransgenic mice. Nature 331 (1988) 267
23. Palacios R., and Steinmetz M. IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocyte in vivo. Cell 41 (1985) 727
24. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380
25. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., and Vetto J.T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl. J. Med. 313 (1985) 1485
26. Stauber D.J., Debler E.W., Horton P.A., Smith K.A., and Wilson I.A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2788
27. Tey S.K., Bollard C.M., and Heslop H.E. Adoptive T-cell transfer in cancer immunotherapy. Immunol. Cell Biol. 84 (2006) 281
28. Ueda H., Kawahara M., Aburatani T., Tsumoto K., Todokoro K., Suzuki E., Nishimura H., Schueler P.A., Winter G., Mahoney W.C., Kumagai I., and Nagamune T. Cell-growth control by monomeric antigen: the cell surface expression of lysozyme-specific Ig V-domains fused to truncated Epo receptor. J. Immunol. Methods 241 (2000) 159
29. c Receptors. Science 310 (2005) 1159